Surmodics (NASDAQ:SRDX) Downgraded by StockNews.com to Buy

StockNews.com downgraded shares of Surmodics (NASDAQ:SRDX) from a strong-buy rating to a buy rating in a research note released on Wednesday morning.

Separately, Needham & Company LLC restated a buy rating and issued a $47.00 target price on shares of Surmodics in a report on Wednesday, April 10th.

Surmodics Stock Down 3.2 %

Shares of Surmodics stock opened at $26.07 on Wednesday. The business’s fifty day moving average price is $29.00 and its two-hundred day moving average price is $31.75. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.84 and a quick ratio of 3.97. The company has a market capitalization of $371.24 million, a P/E ratio of 68.61 and a beta of 1.01. Surmodics has a 1-year low of $16.79 and a 1-year high of $39.41.

Institutional Investors Weigh In On Surmodics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Surmodics by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 846,164 shares of the company’s stock worth $27,153,000 after purchasing an additional 19,635 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Surmodics by 18.8% in the 3rd quarter. Acadian Asset Management LLC now owns 354,738 shares of the company’s stock valued at $11,377,000 after acquiring an additional 56,012 shares in the last quarter. Salem Investment Counselors Inc. lifted its stake in Surmodics by 1.3% in the 4th quarter. Salem Investment Counselors Inc. now owns 129,940 shares of the company’s stock valued at $4,723,000 after acquiring an additional 1,700 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Surmodics by 6.4% in the 4th quarter. Russell Investments Group Ltd. now owns 67,845 shares of the company’s stock valued at $2,466,000 after acquiring an additional 4,066 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its stake in Surmodics by 109.8% in the 4th quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock valued at $1,624,000 after acquiring an additional 23,379 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).